Probi AB (OSTO:PROB) Gross-Profit-to-Asset % : 13.10% (As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Probi AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Probi AB's annualized Gross Profit for the quarter that ended in Mar. 2024 was kr198.4 Mil. Probi AB's average Total Assets over the quarter that ended in Mar. 2024 was kr1,513.8 Mil. Therefore, Probi AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 13.10%.

Probi AB Gross-Profit-to-Asset % Historical Data

The historical data trend for Probi AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probi AB Gross-Profit-to-Asset % Chart

Probi AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

23.34

24.51

21.56

17.02

14.39

Probi AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															18.48	11.73	12.87	12.79	13.10

Competitive Comparison of Probi AB's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Probi AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Probi AB's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Probi AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Probi AB's Gross-Profit-to-Asset % falls into.

Probi AB Gross-Profit-to-Asset % Calculation

Probi AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	220.213	/	( (1569.888	+	1490.443)	/ 2 )
	=	220.213	/	1530.1655
	=	14.39 %

Probi AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	198.368	/	( (1490.443	+	1537.135)	/ 2 )
	=	198.368	/	1513.789
	=	13.10 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Probi AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Probi AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Probi AB (OSTO:PROB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Probi AB (OSTO:PROB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

PBBIF:USA

Address

Ideongatan 1 A, Lund, SWE, SE-223 70

Website

https://www.probi.com

Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. The company's research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).

Probi AB (OSTO:PROB) Headlines

No Headlines